Helicobacter最新文献

筛选
英文 中文
Efficacy of Tegoprazan-Containing Sequential Eradication Treatment Compared to Esomeprazole-Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study 在抗菌药耐药性较高的韩国地区,含替戈拉赞的幽门螺杆菌序贯根除治疗与含埃索美拉唑的序贯根除治疗的疗效比较:一项前瞻性、随机、单一三级中心研究。
IF 4.3 2区 医学
Helicobacter Pub Date : 2024-10-22 DOI: 10.1111/hel.13143
Jung Won Lee, Nayoung Kim, Jongchan Lee, So Young Jo, Dong Ho Lee
{"title":"Efficacy of Tegoprazan-Containing Sequential Eradication Treatment Compared to Esomeprazole-Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study","authors":"Jung Won Lee,&nbsp;Nayoung Kim,&nbsp;Jongchan Lee,&nbsp;So Young Jo,&nbsp;Dong Ho Lee","doi":"10.1111/hel.13143","DOIUrl":"10.1111/hel.13143","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Treatment with potassium-competitive acid blockers has shown acceptable efficacy in <i>Helicobacter pylori</i> eradication. In regions like Korea, where the clarithromycin resistance rate is high, alternative combinations like non-bismuth quadruple therapies have shown favorable results. This study compared the outcomes of sequential eradication therapy with new potassium-competitive acid blocker tegoprazan and conventional esomeprazole-containing sequential therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Patients with <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection were consecutively recruited. Patients were allocated to either an esomeprazole-containing sequential or a tegoprazan-containing sequential therapy group. Sequential therapy comprised esomeprazole (40 mg) or tegoprazan (50 mg) plus amoxicillin (1000 mg) twice daily for the initial 5 days, followed by esomeprazole (40 mg) or tegoprazan (50 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice daily for the remaining 5 days. Eradication rate, compliance, and adverse events were recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 406 patients with <i>H. pylori</i> infection were enrolled in the trial and analyzed per protocol. Eradication rate by intention-to-treat and per-protocol was 83.8% (95% confidence interval [CI]: 78.7–88.9) for esomeprazole-containing sequential therapy, and 87.1% (95% CI: 82.5–91.8) for tegoprazan-containing sequential therapy, with no statistical significance (<i>p</i> = 0.399). Additionally, there was no statistically significant difference in treatment compliance between the two groups. Nausea was more prevalent (23.3%, 27/202) with sequential tegoprazans than with esomeprazole-containing sequential therapy (14.2%, 29/204; <i>p</i> = 0.022).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Tegoprazan-containing 10-day sequential eradication treatment demonstrated similar eradication efficacy compared to esomeprazole-containing treatment, even in regions with high antimicrobial resistance, such as Korea.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov: NCT06382493</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.13143","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children—Data From the RENIHp Registry 铋疗法根除儿童幽门螺旋杆菌的疗效--来自 RENIHp 登记处的数据。
IF 4.3 2区 医学
Helicobacter Pub Date : 2024-10-09 DOI: 10.1111/hel.13142
Gonzalo Botija, Gonzalo Galicia, Beatriz Martínez, Carmen Cuadrado, Marta Soria, Sonia Fernández, Pedro Urruzuno, María-Luz Cilleruelo, SEGHNP H. pylori Working Group
{"title":"Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children—Data From the RENIHp Registry","authors":"Gonzalo Botija,&nbsp;Gonzalo Galicia,&nbsp;Beatriz Martínez,&nbsp;Carmen Cuadrado,&nbsp;Marta Soria,&nbsp;Sonia Fernández,&nbsp;Pedro Urruzuno,&nbsp;María-Luz Cilleruelo,&nbsp;SEGHNP H. pylori Working Group","doi":"10.1111/hel.13142","DOIUrl":"10.1111/hel.13142","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the efficacy of colloidal bismuth subcitrate (CBS) therapy for the eradication of <i>H. pylori</i> in patients from a national pediatric registry of <i>H. pylori</i> infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Spanish Registry of Children with <i>H. pylori</i> Infection (RENIHp) is a national, multi-center, prospective, non-interventional registry that includes children aged 5–18 years with <i>H. pylori</i> infection diagnosed by endoscopy. All patients in the registry who were treated with CBS between the period 2020 and 2023 were included in this study. The primary outcome was the eradication rate, which was assessed using a <sup>13</sup>C-urea breath test or monoclonal antigen in the stool 6–8 weeks post-treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The registry included 682 patients, 38 (5.6%) of whom underwent treatment with CBS. Fifty percent (19/38) of patients had previously undergone unsuccessful eradication treatment. In 78.9% (30/38) of patients, treatment was guided by an antibiotic sensitivity test. In the remaining patients, an empirical approach was employed. The CBS therapies used were as follows: quadruple therapy with proton pump inhibitors (PPIs), CBS, amoxicillin, and metronidazole (MET) [18/38 (47.3%)]; quadruple therapy with PPIs, CBS, tetracycline, and MET [13/38 (34.2%)]; and other therapies [7/38 (18.4%)]. Thirty-two patients (84.2%) treated with CBS were followed-up with eradication monitoring. The overall eradication rate in patients treated with CBS was 93.8% (30/32, [95% CI: 85.4%–100%]), whereas it was 86.7% in patients in the registry who were not on CBS treatment (430/496, [95% CI: 83.3%–89.5%], <i>p</i> = 0.208). In the six patients with dual resistance to clarithromycin (CLA) and MET who were treated with quadruple therapy with CBS, the eradication rate was 100% (<i>n</i> = 6/6, [95% CI: 61.0%–100%]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>CBS therapies in our registry, although only used in selected cases and at lower than recommended levels, were very effective and showed an eradication rate of &gt; 90%.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic Review and Meta-Analysis: Bismuth Enhances the Efficacy for Eradication of Helicobacter pylori 系统回顾与元分析:铋能增强根除幽门螺旋杆菌的疗效。
IF 4.3 2区 医学
Helicobacter Pub Date : 2024-10-09 DOI: 10.1111/hel.13141
A Reum Choe, Chung Hyun Tae, Miyoung Choi, Ki-Nam Shim, Hye-Kyung Jung
{"title":"Systematic Review and Meta-Analysis: Bismuth Enhances the Efficacy for Eradication of Helicobacter pylori","authors":"A Reum Choe,&nbsp;Chung Hyun Tae,&nbsp;Miyoung Choi,&nbsp;Ki-Nam Shim,&nbsp;Hye-Kyung Jung","doi":"10.1111/hel.13141","DOIUrl":"10.1111/hel.13141","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In the eradication of <i>Helicobacter pylori</i>, the efficacy of bismuth remains inconclusive. We aimed to compare the efficacy of bismuth on various <i>H. pylori</i> eradication regimens.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Randomized controlled trials were collected to compare the efficacy of bismuth to nonbismuth regimens in <i>H. pylori</i> eradication. We pooled information to study eradication, adverse events, and drug compliance. In addition, subgroup analyses for eradication efficacy were performed according to high or low clarithromycin-resistance area, bismuth drug form, and amount of bismuth element.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Records for a total of 2506 patients in 15 trials from 13 randomized controlled studies were included. The eradication of <i>H. pylori</i> was superior when bismuth compared to nonbismuth regimen (odds ratio [OR] = 1.63, 95% confidence interval [CI], 1.33–2.00 in intention-to-treat [ITT]; OR = 2.05, 95% CI, 1.58–2.68 in per-protocol [PP] analyses), without significant difference in drug compliance or adverse events. Bismuth regimens in the high clarithromycin resistance area tend to enhance the eradication rate (OR = 1.66, 95% CI, 1.34–2.05 in ITT; OR = 2.22, 95% CI, 1.67–2.95 in PP analyses). Bismuth potassium citrate and bismuth subcitrate were more effective drug forms in regard to eradication rate. Bismuth at a dosage of &lt; 500 mg/day was significantly higher for the eradication rate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Bismuth to the <i>H. pylori</i> eradication regimens achieve a higher eradication rate, especially in the high clarithromycin resistance area. It could be an eradication option achieving sufficient resistance rates without increasing antibiotic resistance, side effects, or poor compliance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.13141","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tracking the Helicobacter pylori Epidemic in Adults and Children in China 追踪幽门螺杆菌在中国成人和儿童中的流行情况。
IF 4.3 2区 医学
Helicobacter Pub Date : 2024-09-28 DOI: 10.1111/hel.13139
Zixing Wang, Yaoda Hu, Ran Fei, Wei Han, Xiaoxiao Wang, Dongbo Chen, Shaoping She
{"title":"Tracking the Helicobacter pylori Epidemic in Adults and Children in China","authors":"Zixing Wang,&nbsp;Yaoda Hu,&nbsp;Ran Fei,&nbsp;Wei Han,&nbsp;Xiaoxiao Wang,&nbsp;Dongbo Chen,&nbsp;Shaoping She","doi":"10.1111/hel.13139","DOIUrl":"10.1111/hel.13139","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The <i>Helicobacter pylori</i> epidemic in China accounts for up to a third of gastric cancers worldwide. We aim to monitor the temporal and spatial dynamics of <i>H</i>. <i>pylori</i> infection in both adults and children across China.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We developed a surveillance system consisting of a data collection component that harnessed survey reports in natural populations and an analysis component that accounted for the differences in survey time and location, population age structure, and <i>H</i>. <i>pylori</i> detection method. System outputs were estimates of the prevalence of <i>H</i>. <i>pylori</i> in adults and children (aged ≤ 14 years) presented at three hierarchical levels (regional, provincial, and prefectural).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The overall prevalence of <i>H</i>. <i>pylori</i> infection declined sharply in adults (63.3%, 52.5%, 43.4%, and 38.7%) and less sharply in children (23.1%, 26.1%, 16.0%, and 15.7%) in 1983–1999, 2000–2009, 2010–2014, and 2015–2019, respectively. The changes were asynchronous across regions, with the most marked declines in the Northwest, the Hong Kong-Macao-Taiwan region, and the East. We estimated that 457.6 million adults and 44.5 million children have been infected with <i>H</i>. <i>pylori</i>, with cross-province disparities in prevalence ranging from 24.3% to 69.3% among adults and 2.9% to 46.3% among children. In general, the risk level of gastric cancer increased as the prevalence of <i>H</i>. <i>pylori</i> increased. The correlation was statistically significant for both adult men (Spearman coefficient of correlation: 0.393, <i>p</i> = 0.0146) and women (0.470, <i>p</i> = 0.0029).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The tracking system would be important for the continuous and stratified tracking of the <i>Helicobacter pylori</i> epidemic across China and can be used to furnish an evidence base for the formulation of tailored prevention strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142345815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge and Practices of Helicobacter pylori Infection Management Among Physicians in Gansu Province, China: A Cross-Sectional Study 中国甘肃省医生对幽门螺杆菌感染管理的认识和实践:横断面研究
IF 4.3 2区 医学
Helicobacter Pub Date : 2024-09-27 DOI: 10.1111/hel.13137
Na Liu, Qian Luo, Lingzhu Gou, Xiping Shen, Dekui Zhang
{"title":"Knowledge and Practices of Helicobacter pylori Infection Management Among Physicians in Gansu Province, China: A Cross-Sectional Study","authors":"Na Liu,&nbsp;Qian Luo,&nbsp;Lingzhu Gou,&nbsp;Xiping Shen,&nbsp;Dekui Zhang","doi":"10.1111/hel.13137","DOIUrl":"https://doi.org/10.1111/hel.13137","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Physicians' knowledge and practices regarding the diagnosis, treatment, and follow-up of <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection can impact the effectiveness of eradication therapy. This study aimed to investigate the current state of knowledge and practices concerning <i>H. pylori</i> infection management among physicians in Gansu Province, northwest China.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>From October to November 2023, 557 physicians from 14 cities and prefectures in Gansu Province participated in this multicenter cross-sectional study and completed a survey questionnaire.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 519 valid questionnaires were collected. 43.2% of the physicians supported <i>H. pylori</i> screening for high-risk populations or individuals with <i>H. pylori</i>–related diseases. The awareness of target screening populations varied among these physicians, ranging from 69.6% to 98.2%. Most physicians preferred the urea breath test (UBT) as the method for diagnosing <i>H. pylori</i> infection (98.3%) and for follow-up after eradication therapy (98.5%). 89.6% of the physicians preferred bismuth-containing quadruple therapy for initial eradication, with amoxicillin and clarithromycin being the most commonly used antibiotic combination (56.3%). In addition, 84.6% of the physicians indicated that they would inquire about the antibiotic usage history for most patients before treatment, 93.8% would ask patients about their previous eradication history, and 94.2% would inform patients about treatment-related considerations. However, only 43.5%, 27.7%, and 29.7% of the physicians were aware of the high resistance rates of <i>H. pylori</i> to clarithromycin, levofloxacin, and metronidazole, respectively, in Gansu Province. Subgroup analysis revealed that the performance of gastroenterologists, nongastroenterologists, and physicians from different levels of hospitals differed in the diagnosis, treatment, and follow-up of <i>H. pylori</i> infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Knowledge and practices regarding <i>H. pylori</i> infection management among physicians in Gansu Province, China, need further improvement. Strengthening targeted continuing education to increase the overall management level of <i>H. pylori</i> infection is recommended.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study 优化米诺环素含铋四联疗法对幽门螺旋杆菌的拯救治疗:真实世界证据研究。
IF 4.3 2区 医学
Helicobacter Pub Date : 2024-09-22 DOI: 10.1111/hel.13138
Yu Huang, Shuhan Qiu, Yixian Guo, Jinnan Chen, Meixuan Li, Zhaohui Ding, Wei Zhang, Xiao Liang, Hong Lu
{"title":"Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study","authors":"Yu Huang,&nbsp;Shuhan Qiu,&nbsp;Yixian Guo,&nbsp;Jinnan Chen,&nbsp;Meixuan Li,&nbsp;Zhaohui Ding,&nbsp;Wei Zhang,&nbsp;Xiao Liang,&nbsp;Hong Lu","doi":"10.1111/hel.13138","DOIUrl":"10.1111/hel.13138","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The optimal dosage of minocycline remains unclear for <i>Helicobacter pylori</i> (<i>H. pylori</i>) eradication. We aimed to evaluate the efficacy and safety of four different regimens with minocycline and metronidazole compared to classical bismuth quadruple therapy for <i>H. pylori</i> rescue treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>From March 2021 to March 2024, refractory <i>H. pylori</i>-infected patients with at least two previous treatment failures who received 14-day therapy with b.i.d. proton pump inhibitor 20 mg and bismuth 220 mg, plus tetracycline 400 mg q.i.d and metronidazole 400 mg q.i.d (BQT), or minocycline 50 mg q.i.d and metronidazole 400 mg q.i.d (PBMn<sub>4</sub>M<sub>4</sub>), or minocycline 50 mg t.i.d and metronidazole 400 mg t.i.d (PBMn<sub>3</sub>M<sub>3</sub>), or minocycline 50 mg b.i.d and metronidazole 400 mg q.i.d (PBMn<sub>2</sub>M<sub>4</sub>), or minocycline 50 mg b.i.d and metronidazole 400 mg t.i.d (PBMn<sub>2</sub>M<sub>3</sub>) were included in this retrospective study. <i>H. pylori</i> eradication was assessed by <sup>13</sup>C-urea breath test at least 6 weeks after treatment. All adverse effects during treatment were recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Totally, 823 patients were enrolled: 251 with BQT, 97 with PBMn<sub>4</sub>M<sub>4</sub>, 191 with PBMn<sub>3</sub>M<sub>3</sub>, 108 with PBMn<sub>2</sub>M<sub>4</sub>, and 176 with PBMn<sub>2</sub>M<sub>3</sub>. The eradication rates of BQT, PBMn4M4, PBMn3M3, PBMn2M4, and PBMn2M3 were 89.2%, 87.6%, 91.6%, 88.0%, and 91.5%, respectively, by intention-to-treat analysis; 96.1%, 97.7%, 97.8%, 96.9%, and 97.6%, respectively, by modified intention-to-treat analysis; 97.1%, 97.5%, 97.7%, 96.8%, and 97.6%, respectively, by per-protocol analysis. Metronidazole resistance did not affect the efficacy of all groups. PBMn<sub>2</sub>M<sub>3</sub> group achieved the greatest compliance and the fewest moderate and severe adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The novel bismuth-containing quadruple therapy with a low dose of minocycline and metronidazole is an alternative to classical bismuth quadruple therapy for <i>H. pylori</i> rescue treatment with superior safety and compliance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: NCT06332599</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid Antimicrobial Susceptibility Test of Helicobacter pylori to Metronidazole via Single-Cell Raman Spectrometry 通过单细胞拉曼光谱法快速检测幽门螺杆菌对甲硝唑的抗菌药敏感性
IF 4.3 2区 医学
Helicobacter Pub Date : 2024-09-16 DOI: 10.1111/hel.13136
Lu Sun, Min Liu, Yanan Gong, Kangle Zhai, FengYun Lv, Lihua He, Xinguang Xue, Xiaolu Liu, Hairui Wang, Dongjie Fan, Yuanhai You, Mengyang Fang, Luyang Sun, Jian Xu, Jianzhong Zhang
{"title":"Rapid Antimicrobial Susceptibility Test of Helicobacter pylori to Metronidazole via Single-Cell Raman Spectrometry","authors":"Lu Sun,&nbsp;Min Liu,&nbsp;Yanan Gong,&nbsp;Kangle Zhai,&nbsp;FengYun Lv,&nbsp;Lihua He,&nbsp;Xinguang Xue,&nbsp;Xiaolu Liu,&nbsp;Hairui Wang,&nbsp;Dongjie Fan,&nbsp;Yuanhai You,&nbsp;Mengyang Fang,&nbsp;Luyang Sun,&nbsp;Jian Xu,&nbsp;Jianzhong Zhang","doi":"10.1111/hel.13136","DOIUrl":"https://doi.org/10.1111/hel.13136","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Metronidazole is a first-line antibiotic to treat <i>Helicobacter pylori</i> infections. However, the Clinical Laboratory Standards Institute guidelines recommend against using antimicrobial susceptibility test (AST) to test metronidazole resistance, due to the unreliable predictive power which can result in treatment failure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim of this study was to establish an 8-h, metabolic-phenotype based AST for <i>H</i>. <i>pylori</i> metronidazole susceptibility using D<sub>2</sub>O-probed Raman microspectroscopy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Minimal inhibitory concentration (MIC) measured by conventional AST (E-test) were compared with expedited MIC via metabolic activity (eMIC-MA) for 10 <i>H</i>. <i>pylori</i> isolates. Raman barcodes of cellular-response to stress (RBCS) incorporating protein and carbohydrate Raman bands, were utilized to identify a biomarker to distinguish metronidazole susceptibility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Specifically, eMIC-MA produces metronidazole susceptibility results showing 100% agreement with E-test, and determines the bactericidal dosage for both high- and low-level resistant <i>H</i>. <i>pylori</i> strains. In addition, RBCS not just reliably distinguish between metronidazole-susceptible and -resistant strains, but reveal their distinct mechanisms in bacterial responses to metronidazole.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The speed, accuracy, low cost, and rich information content that reveals the mode-of-action of drugs suggest the method's value in guiding metronidazole prescriptions for <i>H</i>. <i>pylori</i> eradication and in rapid screening based on drug-resistance mechanism.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142234866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to “Long-Term Effects of Fecal Microbiota Transplantation on Gut Microbiota After Helicobacter pylori Eradication With Bismuth Quadruple Therapy: A Randomized Controlled Trial” 更正:"使用四联铋剂疗法根除幽门螺杆菌后,粪便微生物群移植对肠道微生物群的长期影响:随机对照试验"
IF 4.3 2区 医学
Helicobacter Pub Date : 2024-09-12 DOI: 10.1111/hel.13127
{"title":"Correction to “Long-Term Effects of Fecal Microbiota Transplantation on Gut Microbiota After Helicobacter pylori Eradication With Bismuth Quadruple Therapy: A Randomized Controlled Trial”","authors":"","doi":"10.1111/hel.13127","DOIUrl":"https://doi.org/10.1111/hel.13127","url":null,"abstract":"<p>J. T. Zhao, Y. Zhang, X. W. Wang, et al., “Long-Term Effects of Fecal Microbiota Transplantation on Gut Microbiota After <i>Helicobacter pylori</i> Eradication With Bismuth Quadruple Therapy: A Randomized Controlled Trial,” <i>Helicobacter</i> 29, no. 4 (2024): e13079.</p><p>In the Correspondence section next to the Abstract on the first page, the corresponding author's information was incorrect. Yan-Ling Wei, Dong-Feng Chen and Chun-Hui Lan should all be listed as co-corresponding authors, and the contents are as follows:</p><p>Chun-Hui Lan, Department of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University, Chongqing, China. Email: <span>[email protected]</span>.</p><p>Dong-Feng Chen, Department of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University, Chongqing, China. Email: <span>[email protected]</span>.</p><p>Yan-Ling Wei, Department of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University, Chongqing, China. Email: <span>[email protected]</span>.</p><p>We apologize for this error.</p>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.13127","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated With Decision to Treat or Not to Treat Helicobacter pylori Infection in Children: Data From the EuroPedHp Registry 决定治疗或不治疗儿童幽门螺杆菌感染的相关因素:来自 EuroPedHp 登记处的数据
IF 4.3 2区 医学
Helicobacter Pub Date : 2024-09-09 DOI: 10.1111/hel.13134
Thu Giang Le Thi, Katharina Werkstetter, Kallirroi Kotilea, Patrick Bontems, José Cabral, Maria Luz Cilleruelo, Michal Kori, Josefa Barrio, Matjaž Homan, Nicolas Kalach, Rosa Lima, Marta Tavares, Pedro Urruzuno, Zrinjka Misak, Vaidotas Urbonas, Sibylle Koletzko, for the Helicobacter pylori Special Interest Group of ESPGHAN
{"title":"Factors Associated With Decision to Treat or Not to Treat Helicobacter pylori Infection in Children: Data From the EuroPedHp Registry","authors":"Thu Giang Le Thi,&nbsp;Katharina Werkstetter,&nbsp;Kallirroi Kotilea,&nbsp;Patrick Bontems,&nbsp;José Cabral,&nbsp;Maria Luz Cilleruelo,&nbsp;Michal Kori,&nbsp;Josefa Barrio,&nbsp;Matjaž Homan,&nbsp;Nicolas Kalach,&nbsp;Rosa Lima,&nbsp;Marta Tavares,&nbsp;Pedro Urruzuno,&nbsp;Zrinjka Misak,&nbsp;Vaidotas Urbonas,&nbsp;Sibylle Koletzko,&nbsp;for the Helicobacter pylori Special Interest Group of ESPGHAN","doi":"10.1111/hel.13134","DOIUrl":"https://doi.org/10.1111/hel.13134","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>European and North-American guidelines on management of <i>H. pylori</i> infection in children provide the option not to treat even if the infection is endoscopically confirmed. We used data from the EuroPed<i>Hp</i> Registry to identify factors associated with therapy decisions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We included treatment-naïve patients reported between 2017 and 2020 from 30 centers in 17 European countries. Multivariable logistic regression identified factors including comorbidities within and outside the gastrointestinal (GI) tract influencing the decision for or against therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 1165 patients (52% females, median age 12.8), 28% (321/1165) reported any alarm symptom, 26% (307/1165) comorbidities, and 16% (192/1165) did not receive eradication treatment. Therapy was initiated less often in children having any GI comorbidity (57%, <i>n</i> = 181), particularly in those with eosinophilic esophagitis (60%, <i>n</i> = 35), inflammatory bowel disease (54%, <i>n</i> = 28), and celiac disease (43%, <i>n</i> = 58), compared to those with non-GI (86%, <i>n</i> = 126) or no comorbidity (89%, <i>n</i> = 858), despite similar frequencies of alarm and non-alarm symptoms, ulcers, erosions, and nodular gastritis. Patients with GI and without comorbidities remained more likely untreated in high versus low <i>H. pylori</i> prevalence countries (<i>p</i> &lt; 0.0001). In children without comorbidities, factors favoring therapy included older age, being overweight, having symptoms, erosions, antral nodularity, and available antibiotic susceptibility results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this cohort, <i>H. pylori-</i>infected children with GI comorbidities compared to no comorbidity showed 75% reduced chance of receiving eradication therapy. We found no evidence supporting different management strategies in infected patients with GI comorbidities compared to all pediatric patients with endoscopically proven <i>H. pylori</i> infection.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.13134","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142160146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastric Cancer Screening: Intention to Adhere and Patients' Perspective 胃癌筛查:坚持筛查的意愿和患者的观点
IF 4.3 2区 医学
Helicobacter Pub Date : 2024-09-09 DOI: 10.1111/hel.13135
João Carlos Silva, Mário Dinis-Ribeiro, Fernando Tavares, Diogo Libânio
{"title":"Gastric Cancer Screening: Intention to Adhere and Patients' Perspective","authors":"João Carlos Silva,&nbsp;Mário Dinis-Ribeiro,&nbsp;Fernando Tavares,&nbsp;Diogo Libânio","doi":"10.1111/hel.13135","DOIUrl":"https://doi.org/10.1111/hel.13135","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Gastric cancer (GC) is the third cause of cancer mortality worldwide. A screening strategy that combines an upper gastrointestinal endoscopy (UGIE) with a screening colonoscopy may be cost-effective in intermediate-risk regions. This study aimed to evaluate the intention to adhere to combined endoscopic screening and assess knowledge of GC symptoms, risk factors, and barriers to screening.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Cross-sectional study enrolling individuals eligible for CRC screening in northern Portugal, where a populational fecal occult blood test (FOBT) program is implemented. The validated PERCEPT-PREVENT tool was applied across three groups: (a) not yet invited to CRC screening, (b) FOBT-positive referred to colonoscopy, and (c) primary colonoscopy screening.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A high acceptance rate was observed for combined endoscopic screening (94%; <i>n</i> = 264) [not yet invited to CRC screening 98% (<i>n</i> = 90) vs. FOBT-positive referred to colonoscopy 90% (<i>n</i> = 103) vs. primary colonoscopy 97% (<i>n</i> = 71); <i>p</i> = 0.017], with the vast majority reporting intention to adhere in the setting of full reimbursement (97%; <i>n</i> = 255). Most respondents were unaware of any possible GC symptom (76%; <i>n</i> = 213), risk factor (73%; <i>n</i> = 205), and UGIE-related complication (85%; <i>n</i> = 237). Regular follow-up with the primary care physician (Odds Ratio (OR) 27.59, 95% confidence interval (CI) 2.99–254.57), lower perceived negative health consequences of UGIE (OR 1.40, 95% CI 1.13–1.74), and lower perceived financial burden (OR 2.46, 95% CI 1.04–5.85) were the only factors independently associated with a higher intention to undergo combined screening.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Willingness to undergo combined endoscopic screening was notably high and positively impacted by lower perceived barriers. Additional efforts should be undertaken to improve levels of digestive health literacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"29 5","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142160173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信